Jubilant Biosys Limited has expanded Jay Sheth’s leadership mandate with his appointment as Head of CDMO, North America, alongside his existing role as AVP, Business Development & Global Head of Venture Capital Relations.

In his expanded role, Sheth will lead the company’s CDMO business development activities across North America, focusing on strengthening client relationships, building strategic partnerships and expanding opportunities across the pharmaceutical and biotechnology ecosystem.

He will continue to oversee Jubilant Biosys’ global venture capital relationships and contribute to the company’s broader business development and growth initiatives.

Sheth brings extensive experience across contract development and manufacturing, drug discovery services, business development and strategic partnerships. 

His previous leadership and commercial roles include positions at Jubilant Biosys, Eurofins Advinus, Syngene International, Shasun, TRG and Zydus Group.

His expanded mandate brings together CDMO business development and venture capital engagement, positioning him to strengthen the company’s relationships with biopharma companies, emerging biotech firms and investment communities in North America and other global markets.

The appointment comes as pharmaceutical and biotechnology companies increasingly seek integrated partners across the drug development value chain. 

Sheth’s experience across scientific services and commercial partnerships is expected to support Jubilant Biosys’ efforts to expand its North American CDMO business and deepen its engagement across the global life sciences ecosystem.